NURS 6630 Assessing and Treating Pediatric Patients With Mood Disorders
NURS 6630 Assessing and Treating Pediatric Patients With Mood Disorders
NURS 6630 Assessing and Treating Pediatric Patients With Mood Disorders
According to theNational Institute of Mental Health,approximately 9% of teenagers from the age of 12 to 17 years have depression disorder in the United States.Ghandour et al., (2019) reported that about 3.2% of African American adolescents presented with suicidal thoughtsin 2018as 1.4%tried to commit. Despite the burden associated with this mental disorder, several treatment options are available to help manage the symptoms and promote the quality of life of children and adolescents with this disorder.
Having Trouble Meeting Your Deadline?
Get your assignment on NURS 6630 Assessing and Treating Pediatric Patients With Mood Disorders completed on time. avoid delay and – ORDER NOW
The assigned case study demonstrates an African American boy child diagnosed with depression. The patient reports symptoms such as irritability, feeling sad, decreased appetite, and withdrawalfrom social gatherings like school. The conducted mental status examination revealed that the patient is suicidal, but has never tried to kill himself. The patient however denies hallucinations and delirium among other psychotic symptoms. Based on clinical practice guidelines and DSM-5 diagnostic criteria,together with a score of 30 on theChildren’s Depression Rating Scale,the patient’s primary diagnosis is depression.
The patient’s age, African American race, and anxiety diagnosis are some of the factors which might affect the choice of drugs for the management of the patient’s symptoms. For instance, most antipsychotic agents are associated with suicidal attempts, among other side effects hence must be monitored closely when use among children and adolescents. Additionally, a study conducted by (Leichsenring et al., 2021) reported that African Americans are more likely tocarry alleles that slow down the metabolism of most antidepressants such as tricyclic antidepressants (TCA), leading to a ‘slowmetabolizer’ phenotype hence higher blood TCA plasma level, in addition to more rapid response. The purpose of this paper is to demonstrate the decision-making process of the most effective medication to include in the patient’s treatment plan, while observing pharmacokinetic and pharmacodynamic factors, in addition to ethical considerations which might impact this care process.
Struggling to Meet Your Deadline?
Get your assignment on NURS 6630 Assessing and Treating Pediatric Patients With Mood Disorders done on time by medical experts. Don’t wait – ORDER NOW!
Decision #1 Top of Form
Selected Decision and Rationale
The initial intervention is to start the patient on Zoloft 25 mg orally once daily. Sertraline belongs to the class of selective serotonin reuptake inhibitors (SSRIs), recommended in national clinical guidelines as the first-line for the management of depression in children and adults (Walkup, 2017).
Considering the patient’s specific factors, Zoloft is the best choice of drug for the management of depressive symptoms displayed by the patient. anxiety symptoms. For instance,most studies recommend the use of sertraline among children as a result of its great effectiveness and desirable safety profile reported by the few conducted clinical trials. The drug acts by inhibiting the central nervous system (CNS) neuronal uptake of serotonin(5HT) (Pile et al., 2020). Among children, the recommended starting dose is 25mg. The drug is absorbed slowly in the GIT with a peak plasma level being attained after 6 to 8 hours, necessary to elicit optimal therapeutic action. Studies have also identified several polymorphisms in genes encoding P-450 isoenzymes (2D6 and 2C19) among African Americans which affect the metabolism of the drug. However, when used in low disease, the drugs have displayed great effectiveness with an appealing safety profile.
Wellbutrin on the other hand is not recommended for children less than 18 years due to evidence deficits in its safety and effectiveness (Ghandour et al., 2019). The drug is also associated with high suicidal incidence, hence not appropriate for this patient as he already displayed symptoms of suicidal ideation. Paxil is also not appropriate for this patient as it is also associated with high suicide incidences as the FDA issued a black box warning for use of the drug among this vulnerable population (Leichsenring et al., 2021). It should only be considered in case there is no other suitable option which in this case is Zoloft as described above.
Expected Outcome
The drug is expected to display at least 50% remission of the patient’s depression symptoms within the next 4 to 8 weeks. As a result, theChildren’s Depression Rating Scalescores are expected to decrease to less than 10 from 30. Only common self-limiting side effects such as dry mouth increased sweating and headache might be expected(Walkup, 2017).
Ethical Considerations
Given that the patient is under the age of 18 years, it will be necessary for the PMHNP to adequately inform the patient’s parents about the available treatment options and their benefits and risks to involve them in decision making concerning the health of their child(Pile et al., 2020). Parents and guardians have legal authority in making healthcare decisions for their children.
In this case study, the patient is an African-American child admitted to the healthcare facility accompanied by the mother. The boy is experiencing symptoms of depression. Some of the reported symptoms include withdrawal, reduced appetite, and often gets angry on the slightest provocation (Laureate Education, 2016). However, the patient exhibits good physical outlook with normal results from the laboratory testing. Additionally, the patient’s developmental stages were all attained at the appropriate age hence the need to carry out more assessment on the patient’s psychological condition.
Further analysis reveals the patient has sad feelings and always thinks about being dead and how it would be like when he is dead. However, he does not approve of committing suicide and has no such ideas in mind. The patient is in a sad mood during the interview but at some points during the interview he smiles normally (Laureate Education, 2016). The purpose of this paper is to consider a proper plan for the treatment of the patient. The plan focuses on the decision tree with emphasis on proper communication with the patient and observance of all the related ethical standards to be met.
Decision Point 1
Begin Zoloft 25 mg orally daily
Why Select Zoloft 25mg Oral Daily Dose?
The drug is classified as an anti-depressant that works on the principle of inhibition of the selective uptake of serotonin. It is the prescribed medication for major depressive disorder (MDD), obsessive compulsive disorder(OCD), panic disorder, posttraumatic stress disorder (PTSD), social anxiety disorder and premenstrual dysphoric disorder (PMDD). The 25mg daily dosage is the appropriate and recommended oral dose for children. Zoloft has proved to be effective in treatment of children with OCD for ages between six and seventeen years (Garland et al., 2016).
What is the expected outcome on making this decision?
This prescribed drug is aimed at reducing the patient’s sad mood, improving the patient’s appetite and boosting their feelings for self and social interactions (Neavin, Joyce & Swintak, 2018). The drug will also alleviate the feelings of death hence making the patient appreciate life and improve his general feeling about life. Additionally, Zoloft is appropriate for the age of the patient who is eight years old and there is less side effects expected on the patient.
Expected Vs. Actual Results
After a period of four weeks the patient returned to the health facility for follow up. The patient still had symptoms of depression. This was contrary from the expected outcome because the SSRIs have a slow action mechanism associated with late improvement of the depression symptoms.
Decision Point 2
Double up the dosage to 50mg daily
Why take this decision?
It is recommended to double up the dosage if the patient does not show any improvement within a period of four weeks (Garland et al., 2016). The use of Prozac 10mg daily dosage is not the appropriate decision at the moment because it is only recommended if there is no improvement of the patient’s condition after six weeks (Neavin et al., 2018).
What is the expected outcome on making this decision?
By doubling up the dosage I hope to improve the patient’s feelings on depression by half and make him feel better emotionally, improve his appetite and social interactions.
Expected Vs. Actual Results
On the second visit to the health facility after period of four weeks, the patient’s state has remarkably improved by half. The patient’s body has shown great tolerance to the drug and the expected and actual results are similar. This can also be attributed to the fact that Zoloft is associated with late improvement in depression patients.
Decision Point 3
Increase to 75 mg orally daily.
Why take this decision?
This decision was achieved at by checking on the patient’s progress. The patient had not achieved full recovery from depression and social withdrawal symptoms. This dosage will sustain the current dosage and improve on the patient’s recovery process. (Neavin et al., 2018).
Other options like the use of SSRI is not appropriate at the moment because the patient has exhibited good response to Zoloft in both treatment and the ability of the patient’s body to tolerate the drug. Additional SSRI has been associated with strong withdrawal symptoms especially when its use is discontinued and this like pose similar symptoms of the relapse to depression (Garland et al., 2016). The relapse of the withdrawal symptoms occurs after a period of between six and eight weeks after treatment with SSRI hence is not the outcome we need for this patient at the moment.
What is the expected outcome on making this decision?
By taking this decision, the aim is to achieve full recovery of the patient from depression and the related symptoms. It is expected after four weeks the patient’s mood would have changed and exhibit happiness coupled with euthymia (Dwyer & Bloch, 2019). Additionally, the patient is expected to have better appetite, proper sleeping patterns, improved social interactions and reduced or no feelings of death.
Expected Vs. Actual Results
After four weeks the patient returned with improved conditions. He was feeling happy and with improved social interactions. This actual results are similar to the expected results.
How Ethical Considerations Might Impact Your Treatment Plan Communication with Clients
One of the key ethical issue to be considered is the right to information and the independence of the client to make the decision that suits the needs. It is important to explain to the patient or the care giver the treatment plans available, their cost and the expected side effects (Katz et al., 2016). This will empower the client with knowledge and ensure that the client makes informed decisions. The case in point involves a child therefore the consent should be obtained from the mother who is the immediate care giver to the child.
Therefore, the mother’s decision will have an impact on the patient’s treatment plan. Another ethical issue to consider is beneficence. This will call upon the health practitioner to offer a treatment plan that is best suited to the patient and will deliver the best desired outcomes. I also allow the health practitioner to modify and improve the treatment plan if the existing one does not produce the desired outcomes. (Katz et al., 2016). Additionally, non-maleficence is another ethical issue that is likely to impact on the treatment plan, this allows the medical practitioner to modify the treatment plan in case the existing one has adverse effects to the patient. It is imperative for the healthcare practitioner to consider all the ethical issues before coming up with the treatment plan and modify it along the way with key emphasis being to ensure that the patient’s outcome is improved and patient satisfaction is met.
Conclusion
The case in point was an eight-year-old African-American boy with a depression disorder that exhibited various symptoms such as reduced appetite, social withdrawal and feelings of death. The boy is treated with Zoloft initial dosage of 25mg daily but after four weeks the symptoms had not improved is can be attributed to the late action of the Zoloft drug The dosage was doubled to 50mg daily and the symptoms improved by half after another four weeks. On further increase of the dosage to 75mg daily for another four weeks, the patient’s condition greatly improved and the patient exhibited happiness, improved appetite, better sleep and general feeling of euthymia. The treatment plan considered ethical factors such as patient’s autonomy, beneficence and non-maleficence as the key to better patient outcomes.
References
Dwyer, J. B., & Bloch, M. H. (2019). Antidepressants for Pediatric Patients. Current Psychiatry, 18(9), 26–42F. PMC6738970/
Jane Garland, E., Kutcher, S., Virani, A., & Elbe, D. (2016). Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l’Academie Canadienne de Psychiatrie de l’enfant et de l’adolescent, 25(1), 4–10. PMC4791100/
Katz, A. L., & Webb, S. A. (2016). Informed Consent in Decision-Making in Pediatric Practice. Pediatrics, 138(2), e20161485. https://doi.org/10.1542/peds.2016-1485
Neavin, D., Joyce, J., & Swintak, C. (2018). Treatment of Major Depressive Disorder in Pediatric Populations. Diseases, 6(2), 48. https://doi.org/10.3390/diseases6020048
When pediatric patients present with mood disorders, the process of assessing, diagnosing, and treating them can be quite complex. Children not only present with different signs and symptoms than adult patients with the same disorders, they also metabolize medications much differently. Yet, there may be times when the same psychopharmacologic treatments may be used in both pediatric and adult cases with major depressive disorders. As a result, psychiatric nurse practitioners must exercise caution when prescribing psychotropic medications to these patients. For this Assignment, as you examine the patient case study in this week’s Learning Resources, consider how you might assess and treat pediatric patients presenting with mood disorders.
To prepare for this Assignment:
- Review this week’s Learning Resources, including the Medication Resources indicated for this week.
- Reflect on the psychopharmacologic treatments you might recommend for the assessment and treatment of pediatric patients requiring antidepressant therapy.
The Assignment: 5 pages
Examine Case Study: An African American Child Suffering From Depression. You will be asked to make three decisions concerning the medication to prescribe to this patient. Be sure to consider factors that might impact the patient’s pharmacokinetic and pharmacodynamic processes.
At each decision point, you should evaluate all options before selecting your decision and moving throughout the exercise. Before you make your decision, make sure that you have researched each option and that you evaluate the decision that you will select. Be sure to research each option using the primary literature.
Introduction to the case (1 page)
- Briefly explain and summarize the case for this Assignment. Be sure to include the specific patient factors that may impact your decision making when prescribing medication for this patient.
Decision #1 (1 page)
- Which decision did you select?
- Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
- Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
- What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature).
- Explain how ethical considerations may impact your treatment plan and communication with patients. Be specific and provide examples.
Decision #2 (1 page)
- Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
- Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
- What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature).
- Explain how ethical considerations may impact your treatment plan and communication with patients. Be specific and provide examples.
Decision #3 (1 page)
- Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
- Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature.
- What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature).
- Explain how ethical considerations may impact your treatment plan and communication with patients. Be specific and provide examples.
Conclusion (1 page)
Summarize your recommendations on the treatment options you selected for this patient. Be sure to justify your recommendations and support your response with clinically relevant and patient-specific resources, including the primary literature.
Note: Support your rationale with a minimum of five academic resources. While you may use the course text to support your rationale, it will not count toward the resource requirement. You should be utilizing the primary and secondary literature.
By Day 7
Submit your Assignment.
Submission and Grading Information
To submit your completed Assignment for review and grading, do the following:
- Please save your Assignment using the naming convention “WK4Assgn+last name+first initial.(extension)” as the name.
Grading Criteria
To access your rubric:
Week 4 Assignment Rubric
Check Your Assignment Draft for Authenticity
To check your Assignment draft for authenticity:
Submit your Week 4 Assignment draft and review the originality report.
Submit Your Assignment by Day 7 of Week 4
To participate in this Assignment:
Week 4 Assignment
What’s Coming Up in Week 5?
Photo Credit: [BrianAJackson]/[iStock / Getty Images Plus]/Getty Images
Next week, you will build on your assessment and treatment skills as you examine patients presenting with bipolar disorders.
Next Week
Click here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS: NURS 6630 Assessing and Treating Pediatric Patients With Mood Disorders
Bipolar disorder refers to a chronic psychiatric illness that causes a fluctuation in energy, mood, focus, concentration, and activity. Affected patients present with alternating episodes of mania or hypomania and depression as well as a mixture of manic and depressive features. It damages relationships, lower job performance, and increases suicidal ideations. Bipolar can be managed but residual clinical symptoms and dysfunction can continue making it imperative to continuously reevaluate and treat affected patients. For a deeper understanding of Bipolar disorder, this paper will examine an Asian-American woman diagnosed with the disease and make three decisions regarding her medication. The decisions will be based on pharmacokinetic and pharmacodynamic processes.
Case Study
The presented case outlines a 26-year-old Korean woman. She has Bipolar I disorder a diagnosis made after 21-day hospitalization due to an onset of acute mania. During her appointment, she is exceptionally “busy” as she shifts in her chair and plays with things on the desk (WU, 2022). She reports that she was informed of her bipolar diagnosis but she feels that it’s wrong because her hobbies are talking, dancing, singing, and cooking. Her BMI is normal because she weighs 110lbs and her height is 5’5”. She indicates that her mood is ‘fantastic’ and adds that she sleeps for five hours each night although she hates sleep because it’s no fun.
Her health and lab studies are non -remarkable although she is positive for the CYP2D6*10 allele since all her medications were not working (WU, 2022). Her discharge was authorized after responding positively to Lithium but she states that she no longer takes the prescription as instructed. Her reasons for non-adherence are not offered. Her mental status exam reveals odd dressing because she is wearing an evening gown. She has a tangential, pressured, and rapid speech with a euthymic mood. Her affect is broad with no hallucinations, delusions, to suicidal ideations.
She has intact judgment and impaired insight (WU, 2022). She scores 22 on the Young Mania Rating Scale (YMRS). Among the factors that will influence decisions made are her positive genetic test and her nonadherence history. It will be prudent to consider drugs that limit side effects to enhance compliance. The selected drug should also offer a positive therapeutic response to stabilize and manage her presenting symptoms.
Decision 1
Begin Seroquel XR 300 mg orally at HS
Reason for Selection
Seroquel XR 300 mg was selected because it is a bimodal mood stabilizer that effectively managed bipolar mania and depression. Seroquel blocks dopamine D2 receptors in the mesolimbic pathway resulting in an antipsychotic efficacy. XR 300mg is selected because it is within the recommended therapeutic range. A study by Kanba et al. (2019) outlines that administration of 300mg/day of quetiapine XR greatly reduces the Montgomery–Åsberg Depression Rating Scale score compared to a placebo. The dosage sustains long-term efficiency with no new safety concerns.
Murasaki et al. (2018) also provide similar views in their multi-center, randomized, double-blind, placebo-controlled study. Patients were offered a monotherapy of Quetiapine XR 300Mg or a placebo for eight weeks. The research concluded that the dosage offered once daily, was effective and well-tolerated. The patient has reported non-adherence issues making a once-daily dosage ideal. Seroquel XR has a peak plasma of 5 hours and maintains sufficient therapeutic drug concentration as a single daily dose.
Despite Lithium being a cornerstone of therapy for bipolar disorder, the drug is rejected because of non-compliance. As Pelacchi et al. (2022) explain, the therapeutic window of the drug is narrow yet it has a high incidence of adverse effects and requires repeated serum level controls. It induces side effects like diarrhea, weight gain, polydipsia, polyuria, and tremor which can cause low treatment compliance. Öhlund et al. (2018) executed a retrospective cohort study to understand why patients with bipolar disorder discontinue the medication. Among 873 patients recruited in the study, 561 reported lithium discontinuations. 62% of the discontinuations were linked to adverse events, 44% to psychiatric reasons, and 12% to physical reasons.
Risperdal was rejected because of the patient’s positive genetic test. The patient is positive for the CYP2D6*10 allele a crucial factor when recommending Risperdal. Risperidone i